Tag: LINC 2018

Two-year data from Viabahn BX IDE trial “promising”

The 24-month data from the Viabahn BX Flex balloon-expandable stent (Gore) investigational device exemption (IDE) trial are “promising” with sustained clinical and patency benefits...

Intraoperative oxygen monitoring predicts wound healing in critical limb ischaemia patients...

Preliminary findings from an initial study with 25 patients have shown that measuring the changes in oxygen concentration at baseline, during, and after endovascular...

IN.PACT SFA Japan trial shows significantly higher patency compared with PTA...

New two-year results from the IN.PACT SFA Japan trial were presented at the Leipzig Interventional Course (LINC; 30 January–2 February, Leipzig, Germany) by Osamu...
Serranator Alto

Serrenator Alto first-in-man PRELUDE study results presented at LINC 2018

Cagent Vascular, a developer of technology for vessel dilatation in cardiovascular interventions, has announced positive results from the first-in-human PRELUDE study of the company's...

First-in-man SELUTION study achieves primary endpoint

Primary endpoint data from the first-in-man study of SELUTION, Med Alliance’s novel sirolimus-coated balloon, were presented at the Leipzig Interventional Course (LINC; 29 January–2...

LINC 2018 data highlight IN.PACT Admiral as safe and effective treatment...

Medtronic added to its body of clinical evidence supporting the IN.PACT Admiral drug-coated balloon with new presentations that demonstrated durable and consistent clinical outcomes...